
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter. In Q3, Alnylam Pharmaceuticals brought in $187.63 million in sales but lost $204.51 million in earnings.